Favorable-Risk RCC: Options for VEGF TKI Monotherapy
Comparing IO/TKI and TKI monotherapy for kidney cancerПодробнее
Favorable-Risk RCC: Frontline VEGF TKI/IO CombinationsПодробнее
Treatment of Favorable Risk Renal Cell CarcinomaПодробнее
Which Patients With RCC Are Right for Monotherapy?Подробнее
VEGF TKI Therapy in the Adjuvant Setting of RCCПодробнее
Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCCПодробнее
VEGF-TKI Therapy in First-Line mRCCПодробнее
The Role of Tyrosine Kinase Inhibitors and mTOR InhibitorsПодробнее
Dr. Alva on TKI Monotherapy and Combinations for RCCПодробнее
Second-Line Treatment Options for Advanced RCCПодробнее
Optimizing Patient Outcomes in RCC Through Safe Use of Immuno-Oncology and Targeted ApproachesПодробнее
RCC MasterClass and Clinical Consult: Novel Immune and Targeted TherapiesПодробнее
Poor-Risk Advanced RCC: TKI Therapy & OutlookПодробнее
Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaПодробнее
Expert Guidance on Leveraging Therapeutic Strategies in RCCПодробнее
Clinically Meaningful Outcomes Among Expanding Treatment Options in RCCПодробнее
Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?Подробнее
Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCCПодробнее
Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and MoreПодробнее